Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + sugemalimab in HER2-expressing recurrent or metastatic cervical cancer after platinum failure
CTR20232402Phase 2Active
- Sponsor
- RemeGen
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, sugemalimab in Cervical Cancer (CC), sponsored by RemeGen. Started Jan 2024; status: active.
02
Drugs
disitamab vedotinsugemalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20232402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232402.